Nigel J. M. Birdsall, Sophie Bradley, David A. Brown, Noel J. Buckley, R.A. John Challiss, Arthur Christopoulos, Richard M. Eglen, Frederick Ehlert, Christian C. Felder, Rudolf Hammer, Heinz J. Kilbinger, Günter Lambrecht, Chris Langmead, Fred Mitchelson, Ernst Mutschler, Neil M. Nathanson, Roy D. Schwarz, David Thal, Andrew B. Tobin, Celine Valant, Jurgen Wess
{"title":"Acetylcholine receptors (muscarinic) in GtoPdb v.2023.1","authors":"Nigel J. M. Birdsall, Sophie Bradley, David A. Brown, Noel J. Buckley, R.A. John Challiss, Arthur Christopoulos, Richard M. Eglen, Frederick Ehlert, Christian C. Felder, Rudolf Hammer, Heinz J. Kilbinger, Günter Lambrecht, Chris Langmead, Fred Mitchelson, Ernst Mutschler, Neil M. Nathanson, Roy D. Schwarz, David Thal, Andrew B. Tobin, Celine Valant, Jurgen Wess","doi":"10.2218/gtopdb/f2/2023.1","DOIUrl":null,"url":null,"abstract":"Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [53]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates. Of note, it has been observed that mAChRs dimerise reversibly [134] and that dimerisation/oligomerisation can be affected by ligands [183, 196].","PeriodicalId":14617,"journal":{"name":"IUPHAR/BPS Guide to Pharmacology CITE","volume":"199 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IUPHAR/BPS Guide to Pharmacology CITE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2218/gtopdb/f2/2023.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [53]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates. Of note, it has been observed that mAChRs dimerise reversibly [134] and that dimerisation/oligomerisation can be affected by ligands [183, 196].